Latest news with #Assisi®Loop
Associated Press
05-03-2025
- Business
- Associated Press
Zomedica Corp. Announces Transition to OTCQB Venture Market
Zomedica's ticker symbol will change to ZOMDF ANN ARBOR, MI / ACCESS Newswire / March 4, 2025 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a leading veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that its common shares will be delisted from the NYSE American exchange, due to their determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the common shares. Zomedica has made arrangements with the OTCQB Venture Market for its shares to begin trading on the OTCQB Venture Market exchange under the ticker symbol 'ZOMDF', effective March 5, 2025. 'While we are disappointed by the delisting of our common shares from NYSE American, this transition to the OTCQB Market continues to allow Zomedica to maintain its strong engagement with investors while allowing us to focus our resources on driving growth and advancing our pipeline of veterinary products,' said Larry Heaton, Chief Executive Officer of Zomedica. 'While our common shares will be trading on OTCQB, the value of the company's assets, and our opportunities for growth remain the same. We remain dedicated to delivering value to our shareholders and the veterinary community as we continue to innovate in the animal health sector.' The company will continue to file periodic reports with the U.S. Securities and Exchange Commission (SEC) and comply with applicable regulatory requirements. Shareholders and investors will continue to have access to real-time trading data, news, and financial disclosures through the OTC Markets website ( and Zomedica's investor relations page. About Zomedica Corp. Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated transition to the OTCQB Market and the company's business outlook. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Factors that may impact future results include, but are not limited to, market conditions, regulatory approvals, and competitive developments. Zomedica disclaims any obligation to update or revise forward-looking statements except as required by law.
Associated Press
26-02-2025
- Business
- Associated Press
Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET
ANN ARBOR, MI / ACCESS Newswire / February 26, 2025 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, March 13, 2025, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and full year ended December 31, 2024. A question-and-answer session will follow management's prepared remarks. Event: Zomedica Corp. Q4 and FY 2024 Financial Results Conference Call Date: Thursday, March 13, 2025 Time: 4:30 p.m. Eastern Time Live Call: +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International) For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Thursday, March 27, 2025 at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 1174148 About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit 1-734-369-2555
Associated Press
12-02-2025
- Business
- Associated Press
Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters
Relocation to More Efficient Space Supports Growth While Reducing Overhead by Over $200,000 Annually ANN ARBOR, MI / ACCESS Newswire / February 12, 2025 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that that Company has relocated its corporate headquarters to a new facility in Ann Arbor, Michigan. 'Our new headquarters marks an exciting milestone for Zomedica. This move not only provides us with a modernized workspace to accommodate our growing team but also allows us to operate more efficiently by significantly reducing our lease expenses,' said Larry Heaton, President and Chief Executive Officer of Zomedica. 'Our priority is to make strategic decisions that drive the long-term success of our company. This new space is not only more functional and appealing but also significantly more cost-effective, allowing us to optimize resources while continuing to invest in innovation and growth.' Zomedica's lease for its prior Ann Arbor headquarters, located on Phoenix Drive, expired on January 31, 2025. Under the new lease, Zomedica reduced square footage by approximately 19%, and reduced base annual rent by approximately 50%, representing more than $200,000 in annual cost savings for Zomedica. 'This move is another way we are working diligently to hit profitability,' said Scott Jordan, Executive Vice President, Finance & Chief Financial Officer of Zomedica. 'By significantly lowering our lease expenses, we are freeing up capital that can be reinvested into the business, accelerating our path to financial sustainability and long-term success.' About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Cautionary Note Regarding Forward-Looking Statements Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Yahoo
12-02-2025
- Business
- Yahoo
Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters
Relocation to More Efficient Space Supports Growth While Reducing Overhead by Over $200,000 Annually ANN ARBOR, MI / ACCESS Newswire / February 12, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that that Company has relocated its corporate headquarters to a new facility in Ann Arbor, Michigan. "Our new headquarters marks an exciting milestone for Zomedica. This move not only provides us with a modernized workspace to accommodate our growing team but also allows us to operate more efficiently by significantly reducing our lease expenses," said Larry Heaton, President and Chief Executive Officer of Zomedica. "Our priority is to make strategic decisions that drive the long-term success of our company. This new space is not only more functional and appealing but also significantly more cost-effective, allowing us to optimize resources while continuing to invest in innovation and growth." Zomedica's lease for its prior Ann Arbor headquarters, located on Phoenix Drive, expired on January 31, 2025. Under the new lease, Zomedica reduced square footage by approximately 19%, and reduced base annual rent by approximately 50%, representing more than $200,000 in annual cost savings for Zomedica. "This move is another way we are working diligently to hit profitability," said Scott Jordan, Executive Vice President, Finance & Chief Financial Officer of Zomedica. "By significantly lowering our lease expenses, we are freeing up capital that can be reinvested into the business, accelerating our path to financial sustainability and long-term success." About ZomedicaZomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $78 million in liquidity as of September 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit Follow Zomedica Email Alerts: LinkedIn: Facebook: X (formerly Twitter): Instagram: Cautionary Note Regarding Forward-Looking StatementsExcept for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact:Zomedica Investor Relationsinvestors@ SOURCE: Zomedica Corp. View the original press release on ACCESS Newswire Sign in to access your portfolio
